Coiled Therapeutics PLC
COIL
Company Profile
Business description
Coiled Therapeutics PLC is an oncology company engaged in pursuing opportunities to find new therapies for cancer. The product pipeline of the company consists of AO-252, a novel TACC3 inhibitor currently in Phase I clinical trials in the USA; and STAT-6 siRNA programme for immunology indications. The principal activity of the Company is to develop pre-clinical development of next-generation medicines focused on hard-to-treat cancers.
Contact
85 Great Portland Street
First Floor
LondonW1W 7LT
GBRT: +44 2039188633
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
Chart of the Week: Recent selloffs in this ASX sector opens doors to opportunity
Ongoing rate hikes have investors spooked.
stocks
ASX dividend champions: Stocks, ETFs and LICs
Mark and Shani run through lessons for ASX stocks, ETFs and LICs that have delivered over the past decade.
stocks
SpaceX’s IPO filing: Big spending, big losses
The first public financials from Elon Musk’s company highlight Starlink’s revenue power and increased spending on AI.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,840.80 | 9.50 | -0.11% |
| CAC 40 | 8,124.40 | 6.98 | 0.09% |
| DAX 40 | 24,771.22 | 33.98 | 0.14% |
| Dow JONES (US) | 50,009.35 | 645.47 | 1.31% |
| FTSE 100 | 10,407.40 | 24.94 | -0.24% |
| HKSE | 25,386.52 | 264.60 | -1.03% |
| NASDAQ | 26,270.36 | 399.65 | 1.54% |
| Nikkei 225 | 61,684.14 | 1,879.73 | 3.14% |
| NZX 50 Index | 12,878.07 | 117.04 | 0.92% |
| S&P 500 | 7,432.97 | 79.36 | 1.08% |
| S&P/ASX 200 | 8,621.70 | 6.30 | -0.07% |
| SSE Composite Index | 4,077.28 | 84.91 | -2.04% |